Want to see IN:LAURUSLABS full AI Analyst Report?
Top Page
Laurus Labs Ltd.
(LAURUSLABS)
Select Model
Select Model
Rating:60Neutral
Price Target:
₹1,935.00
▲(20.76% Upside)
Action:Reiterated
Date:06/06/26
The score is driven primarily by improving profitability and a healthier leverage trend, but is held back by weak/volatile free cash flow and a very high valuation multiple. Technically, the trend is strong, yet overbought indicators increase near-term pullback risk.
Positive Factors
Profitability Rebound
A rebound in revenue and net margin to ~13% indicates improving operating execution and pricing power versus recent troughs. Sustained margin recovery supports reinvestment in capacity and R&D, strengthening long-term earnings power if the company maintains cost discipline.
Negative Factors
Weak Free Cash Flow
Persistently weak or negative free cash flow limits internal funding for capex, working capital and acquisitions, increasing reliance on external financing. Sharp YoY FCF decline despite earnings recovery highlights structural cash conversion issues from capex or working-capital absorption.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Rebound
A rebound in revenue and net margin to ~13% indicates improving operating execution and pricing power versus recent troughs. Sustained margin recovery supports reinvestment in capacity and R&D, strengthening long-term earnings power if the company maintains cost discipline.
Read all positive factors
Laurus Labs Ltd. (LAURUSLABS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹981.15B
Dividend Yield0.11%
Average Volume (3M)107.31K
Price to Earnings (P/E)89.7
Beta (1Y)0.97
Revenue Growth22.62%
EPS Growth114.66%
CountryIN
Employees7,059
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)20.25
Shares Outstanding540,249,600
10 Day Avg. Volume186,027
30 Day Avg. Volume107,314
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)10.11
Price to Sales (P/S)7.86
P/FCF Ratio137.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,700.00Price Target Upside6.10% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)24.69
Revenue Forecast (FY)₹83.33B
Laurus Labs Ltd. Business Overview & Revenue Model
Company Description
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a br...
How the Company Makes Money
Laurus Labs primarily makes money by selling (1) APIs and (2) finished dosage formulations to pharmaceutical companies and through (3) contract development and manufacturing (CDMO) services.
1) Active Pharmaceutical Ingredients (APIs): The compan...
Laurus Labs Ltd. Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
72
Positive
Cash Flow
49
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 72.70B | 68.13B | 55.54B | 50.41B | 60.41B | 49.36B |
| Gross Profit | 34.12B | 27.42B | 29.65B | 25.01B | 31.81B | 26.87B |
| EBITDA | 20.88B | 18.33B | 10.34B | 7.63B | 16.06B | 14.18B |
| Net Income | 10.93B | 8.89B | 3.58B | 1.61B | 7.90B | 8.28B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 105.11B | 93.36B | 83.87B | 76.60B | 69.68B |
| Cash, Cash Equivalents and Short-Term Investments | 1.14B | 1.14B | 1.44B | 1.42B | 484.60M | 759.40M |
| Total Debt | 0.00 | 25.18B | 27.64B | 25.77B | 20.15B | 17.77B |
| Total Liabilities | -54.31B | 50.80B | 47.33B | 42.71B | 36.12B | 36.09B |
| Stockholders Equity | 54.31B | 53.00B | 44.73B | 41.11B | 40.38B | 33.51B |
Cash Flow | ||||||
| Free Cash Flow | 6.04B | 3.89B | -393.50M | -126.20M | 37.40M | 342.60M |
| Operating Cash Flow | 10.93B | 14.59B | 6.02B | 6.66B | 9.94B | 9.11B |
| Investing Cash Flow | -4.77B | -10.95B | -6.82B | -8.22B | -9.96B | -9.14B |
| Financing Cash Flow | -6.68B | -3.54B | 392.80M | 2.50B | -266.40M | 302.60M |
Laurus Labs Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹4.77T | 39.49 | ― | 0.82% | 11.41% | 16.62% | |
75 Outperform | ₹2.14T | 83.25 | ― | 0.41% | 16.35% | 26.84% | |
73 Outperform | ₹1.10T | 20.68 | ― | 0.76% | 23.12% | 62.27% | |
68 Neutral | ₹908.72B | 26.19 | ― | 0.26% | 6.08% | 0.77% | |
61 Neutral | ₹957.40B | 28.90 | ― | 0.69% | -0.92% | -41.73% | |
60 Neutral | ₹981.15B | 89.69 | ― | 0.12% | 22.62% | 114.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:LAURUSLABS
Laurus Labs Ltd.
1,855.00
1,035.39
126.33%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,661.00
619.35
59.46%
IN:DIVISLAB
Divi's Laboratories Limited
8,248.50
2,362.18
40.13%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,172.00
-32.02
-2.66%
IN:LUPIN
Lupin Limited
2,360.00
457.05
24.02%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,949.00
376.66
23.96%
Laurus Labs Ltd. Corporate Events
Laurus Labs Files Q1 FY27 Earnings Call Transcript with Exchanges
Jul 30, 2026
Laurus Labs Ltd. has notified stock exchanges that it conducted its Q1 FY27 earnings conference call on July 24, 2026, following an earlier intimation to investors. The company has made the full transcript of this results call available to the exc...
Laurus Labs’ Composite Scheme of Arrangement Moves to NCLT Hearing in September
Jul 25, 2026
Laurus Labs Limited, a diversified pharmaceutical manufacturer with wholly owned subsidiaries Laurus Synthesis and Sriam Labs, continues to refine its corporate structure to support active pharmaceutical ingredient and contract development activit...
Laurus Labs Posts Audio of Q1 FY27 Earnings Call for Investors
Jul 24, 2026
Laurus Labs has notified the stock exchanges that an audio recording of its Q1 FY27 results conference call, held on July 24, 2026, is now available via a published web link. The disclosure, made under SEBI listing regulations, improves transparen...
Laurus Labs Concludes 21st AGM with Strong Virtual Shareholder Participation
Jul 2, 2026
Laurus Labs Ltd. held its 21st Annual General Meeting on July 2, 2026, via video conferencing and other audio-visual means, with the full board, key management, statutory auditors, and the scrutinizer in attendance. The meeting met quorum requirem...
Laurus Labs strengthens board with new independent directors
Jul 2, 2026
Laurus Labs Ltd., a publicly listed Indian pharmaceutical and life sciences company, focuses on active pharmaceutical ingredients, finished dosage formulations, and contract development and manufacturing services for domestic and international mar...
Laurus Labs shuts trading window ahead of June-quarter results
Jun 29, 2026
Laurus Labs Ltd. has announced the closure of its trading window from July 1, 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code governing insider trading. The restriction applies to de...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.